Akebia Therapeutics, Inc. (AKBA) intrinsic value & 10-year financials
Akebia Therapeutics, Inc. (AKBA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 75.0% a year to $236.2M, with an average return on invested capital of -34.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.67
- Market cap
- $172.3M
- Revenue (FY2025)
- $236.2M
- Revenue growth (10-yr CAGR)
- 75.0%
- ROIC (10-yr avg)
- -34.9%
- Free cash flow (FY2025)
- $67.7M
AKBA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $236.2M | -$5.3M | -$0.02 | $67.7M | 9.9% | -28.9% |
| FY2024 | $160.2M | -$69.4M | -$0.33 | -$40.7M | -31.5% | 113.8% |
| FY2023 | $194.6M | -$51.9M | -$0.28 | — | -23.8% | 579.5% |
| FY2022 | $292.6M | -$92.6M | -$0.51 | -$73.3M | -27.0% | -220.3% |
| FY2021 | $213.6M | -$282.8M | -$1.70 | -$253.0M | -124.2% | -268.2% |
| FY2020 | $295.3M | -$383.5M | -$2.77 | -$110.7M | -127.5% | -153.5% |
| FY2019 | $335.0M | -$279.7M | -$2.36 | -$264.1M | -85.5% | -62.4% |
| FY2018 | $207.7M | -$143.6M | — | -$99.1M | -85.8% | -27.2% |
| FY2017 | $181.2M | -$76.9M | — | -$57.8M | -44.1% | -82.1% |
| FY2016 | $1.5M | -$135.7M | — | $55.2M | -8889.9% | -199.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Akebia Therapeutics, Inc. is a consistent compounder, expanding top-line revenue at 75.0% annually over the past decade.
Akebia Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -0.7% ROIC.
Akebia Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Akebia Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.66 per share.